Research programme: cancer vaccines - Onyvax

Drug Profile

Research programme: cancer vaccines - Onyvax

Alternative Names: Onyvax-L; Onyvax-M; Onyvax-R

Latest Information Update: 01 Jun 2010

Price : $50

At a glance

  • Originator Onyvax
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Lung cancer; Multiple myeloma; Renal cancer

Most Recent Events

  • 05 Mar 2004 This compound is still in active development
  • 13 Feb 2003 Preclinical trials in Renal cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top